RNS Number : 9106D

Omega Diagnostics Group PLC

07 March 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


("Omega" or the "Company" or the "Group")

Result of General Meeting

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, announces that at the General Meeting held earlier today, resolution 1 (an ordinary resolution) passed, but resolution 2 (a special resolution) was not passed.

As a result, the Placing, Subscription and Open Offer will not take place. The Group is therefore not funded to pursue its growth strategy as set out in the Circular. The Directors will now need to reassess the strategy, reflecting on alternative options for funding for the Company and will update the market in due course.

A breakdown of the voting results for each resolution is provided on the Company's website here:


Jag Grewal, Chief Executive Officer, of Omega Diagnostics said: "The Board is encouraged that resolution 1, increasing the Directors' authority to allot shares, was approved by shareholders and notes the views of some retail shareholders with regards to resolution 2 and their pre-emption rights. Accordingly, the fundraise will not proceed and the Company will look at other strategic and funding options."

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 11 February 2022.


 Omega Diagnostics Group PLC                                                           www.omegadx.com 
 Jag Grewal, Chief Executive Officer                                                   via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 finnCap Ltd                                                                        Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore (Corporate 
 Alice Lane/ Charlotte Sutcliffe 
 Walbrook PR Limited                                        Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                                       Mob: 07980 541 893 
 Lianne Applegarth                                                                  Mob: 07584 391 303 
 Sam Allen                                                                          Mob: 07502 558 258 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 07, 2022 10:40 ET (15:40 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Omega Diagnostics Charts.